Eli Lilly and Co (LLY)

Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting

Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Zepbound (tirzepatide) and Shaquille O'Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatable

Zepbound (tirzepatide) and Shaquille O'Neal launch national campaign after NBA legend learns the obstructive...

FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis

FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with...

Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials

Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal...

Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage of menopause

Lilly's Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated...

Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications

Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain...

Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meeting

Lilly to spotlight growing hematology portfolio at 2026 European Hematology Association (EHA) Annual Meeting...

Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities

Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as adjuvant therapy for people with early-stage RET fusion-positive lung cancer

Lilly's Retevmo (selpercatinib) demonstrated an 83% reduction in the risk of disease recurrence or death as...

Form 144 - Report of proposed sale of securities

Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th Scientific Sessions, building toward a new era of choice in diabetes and obesity care

Lilly to present new data on Foundayo, Mounjaro and retatrutide at the American Diabetes Association's 86th...

Foundayo and Zepbound now covered for millions of Americans

Foundayo and Zepbound now covered for millions of Americans PR Newswire INDIANAPOLIS, May 28, 2026 CVS...

Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference

Lilly to participate in Goldman Sachs 47th Annual Global Healthcare Conference PR Newswire INDIANAPOLIS...